> ## Content Index
> Fetch the complete content index at: https://www.theamericanquorum.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Authorizes Novavax COVID-19 Vaccine for U.S. Adults, Adding First Protein-Based Option
- URL: https://www.theamericanquorum.com/taq-historical-2022-07-16-healthcare/
- Published: 2022-07-17T03:59:00.000Z
- Updated: 2022-07-17T03:59:00.000Z
- Description: FDA authorized Novavax's two-dose COVID-19 vaccine for adults 18 and older, adding a protein-based option after trials showed roughly 90% efficacy.
- Author: Kenneth R. Deans Jr.
- Tags: Healthcare, #Import 2026-08-31 14:55

The Food and Drug Administration on Wednesday authorized Novavax's COVID-19 vaccine for adults 18 and older, adding the first protein-based option to the U.S. vaccination program more than a year after messenger-RNA and viral-vector vaccines became widely available. The [FDA authorization](https://www.fda.gov/news-events/press-announcements/actualizacion-sobre-el-coronavirus-covid-19-la-fda-autoriza-el-uso-de-emergencia-de-la-vacuna-contra?ref=theamericanquorum.com) covers a two-dose primary series administered three weeks apart for people who have not yet received a COVID-19 vaccine.

The decision gives clinicians a vaccine built on a platform more familiar from other immunizations. Novavax's NVX-CoV2373 contains recombinant pieces of the SARS-CoV-2 spike protein combined with the company's Matrix-M adjuvant, which is designed to strengthen the immune response. Unlike mRNA vaccines, the product delivers the antigen itself rather than genetic instructions for cells to make it.

Novavax said in its [July 13 announcement](https://ir.novavax.com/press-releases/2022-07-13-U-S-FDA-Grants-Emergency-Use-Authorization-for-Novavax-COVID-19-Vaccine%2C-Adjuvanted-for-Individuals-Aged-18-and-Over?ref=theamericanquorum.com) that doses manufactured by the Serum Institute of India had already been shipped to the United States. Distribution, however, still depends on a recommendation from the Centers for Disease Control and Prevention before the vaccine can be routinely offered.

## A new platform enters a mature vaccine campaign

The timing is important. Most U.S. adults who wanted vaccination have already received Pfizer-BioNTech, Moderna or Johnson & Johnson products, while a substantial minority remains unvaccinated. Federal officials have argued that another technology could appeal to some people who have resisted the existing options, particularly those more comfortable with protein-subunit vaccines that resemble long-used approaches in hepatitis B and other immunizations.

The government prepared for authorization by securing an initial 3.2 million doses. A [July 11 procurement announcement](https://ir.novavax.com/press-releases/2022-07-11-U-S-Government-Secures-3-2-Million-Doses-of-Novavax-COVID-19-Vaccine?ref=theamericanquorum.com) said the doses would be made available free to states, jurisdictions, federal pharmacy partners and federally qualified health centers if FDA authorization and CDC recommendation were obtained. That initial order is small compared with earlier U.S. purchases of mRNA vaccines, reflecting both the late stage of the campaign and uncertainty about demand.

The product is stored at ordinary refrigerator temperatures of 2 to 8 degrees Celsius, a logistical advantage over earlier requirements for ultra-cold storage with some mRNA products. It comes in multidose vials and uses a 5-microgram recombinant spike antigen with 50 micrograms of Matrix-M adjuvant per dose.

## Clinical trials showed about 90% efficacy before Omicron

The FDA's decision rests heavily on the PREVENT-19 trial in the United States and Mexico. The peer-reviewed [New England Journal of Medicine study](https://www.nejm.org/doi/full/10.1056/NEJMoa2116185?ref=theamericanquorum.com) enrolled roughly 30,000 adults and found 90.4% efficacy against symptomatic COVID-19 in the per-protocol population. Moderate-to-severe disease occurred only in placebo recipients during the primary analysis period.

A separate British phase 3 [trial](https://www.nejm.org/doi/full/10.1056/NEJMoa2107659?ref=theamericanquorum.com) reported 89.7% efficacy and similarly low rates of serious adverse events. Those studies were conducted before Omicron became dominant, which means their headline efficacy figures cannot be assumed to describe protection against the variants circulating now. The FDA is therefore authorizing a product with strong evidence against earlier strains but limited direct efficacy data against BA.4 and BA.5.

Safety has also received close scrutiny. In June, the FDA's Vaccines and Related Biological Products Advisory Committee voted 21-0, with one abstention, to recommend authorization. Novavax's [account of that meeting](https://ir.novavax.com/press-releases/2022-06-07-FDA-Advisory-Committee-Recommends-Emergency-Use-Authorization-of-Novavax-COVID-19-Vaccine-for-People-Aged-18-Years-and-Older?ref=theamericanquorum.com) noted that myocarditis events were examined in clinical data. Regulators concluded the benefit-risk balance supported emergency use, while the authorization materials warn about observed myocarditis and pericarditis and call for continued monitoring.

## Authorization does not mean immediate availability

The emergency-use authorization is a major regulatory milestone, but Americans cannot necessarily receive the vaccine immediately. CDC's Advisory Committee on Immunization Practices must evaluate the evidence and make a policy recommendation, after which the CDC director can endorse use. That process determines how the vaccine fits into clinical practice and federal distribution.

Novavax arrives after authorization in numerous other countries. The European Commission granted conditional marketing authorization in December following review by the European Medicines Agency, according to the company's [European authorization announcement](https://ir.novavax.com/press-releases/2021-12-20-European-Commission-Grants-Conditional-Marketing-Authorization-for-Novavax-COVID-19-Vaccine?ref=theamericanquorum.com). The World Health Organization also listed a Serum Institute version for emergency use, giving regulators experience with the platform before the U.S. decision.

What remains uncertain is how much additional vaccination the new option will generate. The United States has already administered hundreds of millions of COVID-19 doses, and the unvaccinated population includes people with a wide range of reasons for declining vaccination. A different platform may address concerns for some, but availability alone may not overcome distrust, access barriers or a belief that vaccination is no longer necessary.

## The near-term test is uptake during a BA.5 wave

The authorization comes as BA.5 is driving a new rise in infections and reinfections. That makes the immediate public-health value of any additional primary-series vaccination straightforward: the strongest benefit of COVID-19 vaccines remains reducing the risk of severe disease, hospitalization and death, even as protection against infection has become less durable with Omicron-lineage variants.

For health systems, the addition of Novavax expands the menu of vaccine technologies and may simplify storage compared with earlier pandemic logistics. For regulators, it adds another product requiring safety surveillance and effectiveness monitoring in a variant environment very different from the one in which pivotal trials were conducted.

The next decision belongs to CDC advisers. If they recommend the vaccine, federal and state programs will begin moving the 3.2 million secured doses into vaccination channels. Novavax will then face the practical test that follows regulatory success: whether a protein-based vaccine arriving in the third year of the pandemic can persuade meaningful numbers of unvaccinated adults to begin a primary series.